Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
- Registration Number
- NCT02242292
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to determine whether hyoscine butylbromide can provide adequate symptomatic relief of a single episode - defined as lasting not longer than 1 day - and multiple episodes of abdominal pain or discomfort associated with cramping when used as needed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 527
Inclusion Criteria
- Adult males and females 18 years of age and older
- Have at least a 3-month self-reported history of recurrent episodic symptoms, usually lasting for 1 hour or more, of self-described abdominal pain or discomfort associated with cramping, which they routinely either have not treated or treated using Over-the-counter (OTC) medications, in which subjects suffered these symptoms at a frequency of at least twice monthly to several times weekly, but not on a daily basis. The episodes of abdominal pain or discomfort may have been associated with other symptoms of GI dysfunction, such as diarrhea, constipation, and bloating
- Symptoms typically have a moderate or greater severity (moderate, severe, very severe) and are sufficiently bothersome to require treatment or intervention
- Symptoms are not associated with abdominal tenderness, swelling, fever, weight loss, or passage of blood per rectum. The onset of symptoms may or may not have been associated with ingestion of food or beverages
- The episodes of abdominal pain or discomfort may have been associated with other symptoms of GI dysfunction, such as diarrhea, cramping, constipation, and bloating
- Subjects are required to be able to comprehend and participate in the activities required for participation in the trial, to have the ability to attend required site visits, and to be available and have the facility to participate in a daily telephone call or computer entry (using a touch-tone phone or computer IVRS entry), which served as the mechanism for diary entry, during the 6-week course of the study. Subjects were required to successfully complete an Interactive voice response system (IVRS) training session prior to entry into the study
- All subjects completed and signed an informed consent form
Exclusion Criteria
- Subjects who reported having these symptoms for the first time, particularly if they were 50 years or older, as this may have been a sign of a more serious organic disease
- Subjects with a known hypersensitivity or allergy to hyoscine butylbromide or any of the inactive ingredients
- Subjects who are currently under a physician's care for abdominal symptoms and/or not using medication or using prescription or OTC medications prescribed by a physician to treat symptoms of abdominal pain, cramping and discomfort or taking prescription medication(s) for the treatment of Irritable bowel syndrome (IBS) (Bentyl® or other antispasmodics, Zelnorm® [tegaserod], Lotronex® [alosetron], prokinetic agents). Current physician's care was defined as the subject presently following clinician advice regarding treatment and management of the abdominal pain or discomfort associated with the cramping symptom
- Subjects who are having symptoms of abdominal swelling, fever associated with symptoms of abdominal pain or discomfort associated with cramping, and/or experiencing passage of blood per rectum associated with symptoms of abdominal pain or discomfort associated with cramping, or who have any evidence of abdominal tenderness (or any other evidence of an acute abdomen), abdominal masses, organomegaly or any other abnormality on abdominal examination
- Subjects with a history of colon or other GI cancer or malignancy, inflammatory bowel disease, or Crohn's disease
- Subjects with chronic constipation
- Subjects with myasthenia gravis or megacolon
- Subjects who have undergone abdominal surgery within the past 2 years, having GI surgery resulting in removal of all or part of the colon, small intestine, or stomach, or having a history of GI by-pass surgery for weight reduction
- Prior history of gallbladder removal, appendectomy, and/or surgery for peptic ulcer disease or gastroesophageal reflux disease (GERD), was not exclusionary.
- Subjects whose major symptoms were retrosternal burning, acid reflux, acid regurgitation, or heartburn are excluded
- Subjects using prescription anticholinergic medications or medications for the treatment of myasthenia gravis, glaucoma, or ocular hypertension are excluded
- Subjects who were currently participating in other trials or who participated in a clinical trial within the prior 30 days are excluded
- Women who reported being pregnant, are nursing, or who are of child-bearing potential and not using an adequate method of birth control (medication, device, abstinence, sterilization for either partner) for 30 days before enrollment and did not agree to continue using an adequate method of birth control for 30 days after completion of the trial are excluded
- Any women of childbearing potential who have a positive serum pregnancy test are excluded
- Post-menopausal women who have been post-menopausal for a duration of less than 2 years and did not have a hysterectomy or tubal ligation procedure are excluded
- Subjects who have tachyarrhythmia (defined as any disturbance of the heart's rhythm, regular or irregular, resulting in a rate over 100 beats per minute) during a physical examination are excluded
- Subjects who have been previously diagnosed with benign prostatic hyperplasia (BPH) or subjects who experienced urinary retention are excluded
- Subjects with clinically significant cardiovascular disease in the opinion of the investigator (including hypotension, hypertension, severe coronary artery disease, congestive heart failure, angina pectoris) are excluded
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Hyoscine butylbromide Hyoscine butylbromide 5 tablets taken in a 24-hour period/each episode: * for up to 7 episodes, or * over a period of up to 6 weeks Placebo Placebo -
- Primary Outcome Measures
Name Time Method Response rate in treating the first episode of abdominal pain or discomfort associated with cramping within 24 hours after starting treatment (Response was defined as achieving adequate relief of symptoms, as measured on a subject's diary using a dichotomized response to the question)
- Secondary Outcome Measures
Name Time Method Number of patients with abnormal changes in laboratory parameters up to 42 days Global Assessment of tolerability by subject on a 4-point scale Day 42 Global assessment of tolerability by investigator on a 4- point scale Day 42 Number of patients with adverse events up to 42 days Time to onset of any effect after the first tablet taken assessed on 5-point scale within 24 hours after starting treatment Time to onset of any effect assessed on 5-point scale up to day 41 Percentage of constipation episodes up to day 41 Global Assessment of efficacy by subject on 4-point scale Day 42 Response rate to trial medication up to day 41 responders were those who obtained adequate relief for 50% or more of all treated episodes
Assessment of Average symptom relief rated on 4-point scale up to day 41 based on the "Symptom Relief Index''
Time to obtain adequate relief after the first tablet taken assessed on 5-point scale within 24 hours after starting treatment Time to obtain adequate relief assessed on 5-point scale up to day 41 Average time to obtain adequate relief per subject assessed on 5-point scale up to day 41 Average number of tablets taken to treat episodes per subject up to day 41 measured for each treated episode by the subject's response to the question on the number of tablets taken for each treated episode or 24-hour period
Percentage of episodes of diarrhea up to day 41 Percentage of bloating episodes up to day 41 Percentage of episodes in relief of abdominal pain or discomfort associated with cramping up to day 41